Open Access
Issue
Med Buccale Chir Buccale
Volume 21, 2015
Gestion péri-opératoire des patients traités par antithrombotiques en chirurgie orale
Page(s) S15 - S81
Section Recommandations
DOI https://doi.org/10.1051/mbcb/2015037
Published online 09 October 2015
  1. Aframian DJ, Lalla RV, Peterson DE. Management of dental patients taking common hemostasis-altering medications. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103 (suppl 1): S45.e1-11. [CrossRef] [Google Scholar]
  2. Agence française de sécurité sanitaire des produits de santé (Afssaps). Commission de Transparence. Tissucol Kit à 500UI de thrombine/ml, poudres et solvants pour colle intralésionnelle 0,5 ml-1 ml-2 ml-5 ml. Avis du 16 juin 1999. [Google Scholar]
  3. Agence française de sécurité sanitaire des produits de santé (Afssaps).Mise au point. Sur le bon usage des médicaments antivitamine K (AVK). Actualisation. Avril 2009. [Google Scholar]
  4. Agence française de sécurité sanitaire des produits de santé (Afssaps). Prévention et traitement de la maladie thromboembolique veineuse. Recommandations de bonne pratique. Décembre 2009. [Google Scholar]
  5. Agence française de sécurité sanitaire des produits de santé (Afssaps). Prescription des antibiotiques en pratique bucco-dentaire. Recommandations. Juillet 2011. [Google Scholar]
  6. Agence française de sécurité sanitaire des produits de santé (Afssaps). Modification des recommandations sur la surveillance plaquettaire d’un traitement par Héparine de Bas Poids Moléculaire. Octobre 2011. [Google Scholar]
  7. Agence française de sécurité sanitaire des produits de santé (Afssaps). Point d’information : Les nouveaux anticoagulants oraux (dabigatran et rivaroxaban) dans la fibrillation auriculaire : Ce qu'il faut savoir. Avril 2012. [Google Scholar]
  8. Agence nationale de sécurité du médicament (Ansm) et Haute Autorité de Santé (HAS). Bon usage des antiplaquettaires. Juin 2012. [Google Scholar]
  9. Agence nationale de sécurité du médicament et des produits de santé (Ansm). Les anticoagulants en France : état des lieux et surveillance. Juillet 2012. [Google Scholar]
  10. Agence nationale de sécurité du médicament et des produits de santé (Ansm). Les anticoagulants en France en 2014 : état des lieux, synthèse et surveillance. Avril 2014. [Google Scholar]
  11. Agence nationale de sécurité du médicament et des produits de santé (Ansm). Plan d’actions de l’ANSM sur les anticoagulants oraux directs en 2013-2014. Juillet 2014. [Google Scholar]
  12. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e44S-88S. [CrossRef] [PubMed] [Google Scholar]
  13. Airoldi F, Colombo A, Morici N. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745-54. [CrossRef] [PubMed] [Google Scholar]
  14. Akopov SE, Suzuki S, Fredieu A, Kidwell CS, Saver SL, Cohen SN. Withdrawal of warfarin prior to surgical procedure: time to follow the guidelines? Cerebrovasc Dis 2005;19:337-42. [CrossRef] [PubMed] [Google Scholar]
  15. Albaladejo P. Synthèse et perspectives (Rivaroxaban). Ann Fr Anesth Rea 2008;27 Suppl 3:S28-31. [CrossRef] [Google Scholar]
  16. Albaladejo P, Godier A, Samama CM. Gestion périopératoire des nouveaux antithrombotiques. Le congrès. Médecins, Les essentiels 2012 Sfar. Page consulté le 29/08/2014 http://sofia.medicalistes.org/spip/IMG/pdf/Gestion_perioperatoire_des_nouveaux_antithrombotiques.pdf [Google Scholar]
  17. Al-Belasy FA, Amer MZ. hemostatic effect of n-Butyl-2 cyanoacrylate(Histoacryl) glue in warfarin treated patients undergoing oral surgery. J Oral Maxillofac Surg 2003;61:1405-9. [CrossRef] [PubMed] [Google Scholar]
  18. Alcok RF, Reddel CJ, Pennings GJ, Hillis GS, Curnow JL, Brieger DB. The rebound phenomenon after aspirin cessation: the biochemical evidence. Int J Cardiol 2014;174:376-8. [CrossRef] [PubMed] [Google Scholar]
  19. Al-Mubarak S, Rass MA, Alsuwyed A, Alabdulaaly A, Ciancio S. Thromboembolic risk and bleeding in patiens maintening or stopping oral anticoagulant therapy during dental extraction. J Thromb Haemost 2006;4:689–91. [CrossRef] [PubMed] [Google Scholar]
  20. Al-Mubarak S, Al-Ali N, Abou-Rass M, Al-Sohail A, Robert A, Al-Zoman K, Al-Suwyed A, Ciancio S. Evaluation of dental extractions, suturing and INR on postoperative bleeding of patients maintained on oral anticoagulant therapy. Br Dent J. 2007;203:E15;discussion 410-1. [CrossRef] [Google Scholar]
  21. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapyfor prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324(7329):71-86. [CrossRef] [PubMed] [Google Scholar]
  22. Antithrombotic Trialists Collaboration (ATT). Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60. [CrossRef] [PubMed] [Google Scholar]
  23. António N, Castro G, Ramos D, Machado A, Gonçalves L, Macedo T, Providência LA. The debate concerning oral anticoagulation: whether to suspend oral anticoagulants during dental treatment. Rev Port Cardiol. 2008;27:531-44. [PubMed] [Google Scholar]
  24. Ardekian L, Gaspar R, Peled M, Brener B, Laufer D. Does low-dose aspirin therapy complicate oral surgical procedures ? J Am Dent Assoc 2000;131:331-35. [CrossRef] [PubMed] [Google Scholar]
  25. Armstrong MJ, Schneck MJ, Biller J. Discontinuation of perioperative antiplatelet and anticoagulant therapy in stroke patients. Neurol Clin. 2006;24:607-30. [CrossRef] [PubMed] [Google Scholar]
  26. Aubertin MA. The patient taking antiplatelets drugs: a review with dental management considerations. General Dentistry 2008:363-69. [Google Scholar]
  27. Autorité de la concurrence. Décision n°10-D16 du 17 mai 2010 relatives à des pratiques mises en œuvre par la société Sanofi-Aventis France. 120 p. www.autorité de la concurrence.fr/pdf/avis/13d11.pdf (page consultée le 04.01.2014). [Google Scholar]
  28. Bacci C, Maglione M, Favero L, Perini A, Di Lenarda R,Berengo M, Zanon E. Management of dental extraction in patients undergoing anticoagulant treatment. Results from a large, multicentre, prospective, case-control study. Thromb Haemost. 2010;104:972-5. [CrossRef] [PubMed] [Google Scholar]
  29. Bacci C, Berengo M, Favero L, Zanon E. Safety of dental implant surgery in patients undergoing anticoagulation therapy: a prospective case-control study. Clin Oral Implants Res. 2011;22:151-6. [CrossRef] [PubMed] [Google Scholar]
  30. Bachman DS. Discontinuing chronic aspirin therapy: another risk factor for stroke? Ann Neurol 2002;51:137-8. [CrossRef] [PubMed] [Google Scholar]
  31. Bacourt F, Foster D, Mignon E. Athérosclérose oblitérante des membres inférieurs. Encycl Med Chir (Elsevier Masson, Paris) Angiologie, 19, 2010. [Google Scholar]
  32. Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematology 2012;159:427-9. [CrossRef] [Google Scholar]
  33. Bajkin BV, Popovic SL, Selakovic SD. Randomized, prospective trial comparing bridging therapy using low-molecular-weight heparin with maintenance of oral anticoagulation during extraction of teeth. J Oral Maxillofac Surg. 2009;67:990-5. [CrossRef] [PubMed] [Google Scholar]
  34. Bajkin BV, Todorovic LM. Safety of local anaesthesia in dental patients taking oral anticoagulants: is it still controversial ? Br J Oral Maxillofac Surg. 2012a;50:65-8. [CrossRef] [PubMed] [Google Scholar]
  35. Bajkin BV, Bajkin IA, Petrovic BB. The effects of combined oral anticoagulant-aspirin therapy in patients undergoing tooth extractions: a prospective study. J Am Dent Assoc. 2012b;143:771-6. [CrossRef] [PubMed] [Google Scholar]
  36. Bajkin BV, Urosevic IM, Stankov KM, Petrovic BB, Bajkin IA. Dental extractions and risk of bleding in patients taking single and dual antiplatelet treatment. Br J Oral Maxillofac Surg 2015;53:29-43. [CrossRef] [Google Scholar]
  37. Balevi B. Should warfarin be discontinued before a dental extraction? A decision-tree analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:691-7. [CrossRef] [PubMed] [Google Scholar]
  38. Bandrowsky T, Vorono A, Borris TJ, Marcantoni HW. Amoxicillin-related postextraction bleeding in an anticoagulated patient with tranexamic acid rinses. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:610-2. [CrossRef] [PubMed] [Google Scholar]
  39. Beirne OR. Evidence to continue oral anticogulant therapy for ambulatory oral surgery. J Oral Maxillofacial Surg 2005;63:540-5. [CrossRef] [Google Scholar]
  40. Biondi-Zoccai GG, Lotrionte M, Agostoni P et al., “A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease,” European Heart Journal 2006, 27:2667-74. [CrossRef] [PubMed] [Google Scholar]
  41. Blinder D, Manor Y, Martinowitz U, Taicher S, Hashomer T. Dental extractions in patients maintained on continued oral anticoagulant: Comparison of local hemostatic modalities. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;88:137-40. [CrossRef] [PubMed] [Google Scholar]
  42. Blinder D, Manor Y, Martinowitz U, Taicher S. Dental extractions in patients maintened on oral anticoagulant therapy: comparison of INR value with occurrence of postoperative bleeding. Int J Oral Maxillofac Surg 2001;30:518-21. [CrossRef] [PubMed] [Google Scholar]
  43. Bloomer CR. Excessive hemorrhage after dental extractions using Low-Molecular-Weight Heparin (Lovenox) anticoagulation therapy. J Oral Maxillofac Surg 2004;62:101-3. [CrossRef] [PubMed] [Google Scholar]
  44. Boisramé-Gastrin S, Abgrall JF, Guillodo MP, Tanne F, Monguillon P. Les examens biologiques en chirurgie orale. In: Editions CdP WKF, editor: Manuel de chirurgie orale technique de réalisation pratique, maîtrise et exercice raisonné au quotidien. collection JPIO;2012:536p. [Google Scholar]
  45. Bodner L, Weinstein JM, Baumgarten AK. Efficacy of fibrin sealant in patients on various levels of oral anticogaulant undergoing oral surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:421-4. [CrossRef] [PubMed] [Google Scholar]
  46. Borea G, Montebugnoli L, Capuzzi P, Magelli C. Tranexamic acid as mouthwash in anticoagulant-treated patients undergoing oral surgery. An alternative method to discontinuing anticoagulant therapy. Oral Surg Oral Med Oral Pathol 1993;75:29-31. [CrossRef] [PubMed] [Google Scholar]
  47. Breik O, Cheng A, Sambrook PJ, Goss AN. Protocol in managing oral surgical patients taking dabigatran. Aust Dent J 2014;59: 296-301. [CrossRef] [PubMed] [Google Scholar]
  48. Brennan MT, Wynn RL, Miller CS. Aspirin and bleeding in dentistry: an update and recommandations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:316-23. [CrossRef] [PubMed] [Google Scholar]
  49. Brennan MT, Hong C, Furney SL, Fox PC, Lockhart PB. Utility of an international normalized ratio testing device in a hospital-based dental practice. J Am Dent Assoc. 2008;139:697-703. [CrossRef] [PubMed] [Google Scholar]
  50. Brennan MT, Valerin MA, Noll JL, Napenas JJ, Kent ML, Fox PC, Sasser HC, Lockhart PB. Aspirin use and post-operative bleeding from dental extractions. J Dent Res 2008;87:740-4. [CrossRef] [PubMed] [Google Scholar]
  51. Broekema F, van Minnen B, Jansma J, Bos RR. Risk of bleeding after dentoalveolar surgey in patients taking anticoagulants. Br J Oral Maxillofac Surg 2014;52:e15-9. [CrossRef] [PubMed] [Google Scholar]
  52. Brooks AS. Delayed complications of tooth extraction in patients taking warfarin, antibiotics, and other medications. J Oral Maxillofac Surg 2011;69:977-9. [CrossRef] [PubMed] [Google Scholar]
  53. Bruggenkate CM, Krekeler G, Kraaijenhagen HA, Foitzik C, Nat P, Oosterbeek HS. Hemmorrhage of the floor of the mouth resulting from lingual peroration during implant placement: a clinical report. Int J Oral Maxillofac Implants 1993;8:329-34. [PubMed] [Google Scholar]
  54. Cañigral A, Silvestre FJ, Cañigral G, Alós M, Garcia-Herraiz A, Plaza A. Evaluation of bleeding risk and measurement methods in dental patients. Med Oral Patol Oral Cir Bucal. 2010;15:e863-8. [CrossRef] [PubMed] [Google Scholar]
  55. Cannon PD, Dharmar VT. Minor oral surgical procedures in patients on oral anticoagulants-a controlled study. Aust Dent J 2003;48: 115-8. [CrossRef] [PubMed] [Google Scholar]
  56. Cardona-Tortajada F, Saint-Gómez E, Figuerido-Garmendia J, de Robles-Adsuar AL, Morte-Casabó A, Giner-Munoz F, et al. Dental extractions in patients on antiplatelet therapy. A study conducted by the Oral Health Departement of the Navarre Health Service (Spain). Med Oral Patol Oral Cir Bucal 2009a;14:e588-92. [PubMed] [Google Scholar]
  57. Carter G, Goss A, Lloyd J, Tocchetti R. Tranexamic acid mouthwash versus autologous fibrin glue in patients taking warfarin undergoing dental extractions: a randomized prospective clinical study. J Oral Maxillofac Surg 2003a;61:1432-5. [CrossRef] [PubMed] [Google Scholar]
  58. Carter G, Goss A. Tranexamic acid mouthwash. A prospective randomized study of a 2-day regimen vs 5-day regimen to prevent postoperative bleeding in anticoagulated patients requiring dental extractions. In J Oral Maxillofac Surg 2003b;32:504-7. [Google Scholar]
  59. Casais P, Sanchez Luceros A, Meschengieser S, Fondevila C, Santarelli MT, Lazzari MA. Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol 2000;63: 192-6. [CrossRef] [PubMed] [Google Scholar]
  60. Chassot PG, Delabays A, Spahn DR, Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction”, British Journal of Anaesthesia 2007;99: 316-28. [CrossRef] [PubMed] [Google Scholar]
  61. Chee YL, Crawford JC, Watson HG, Greaves M. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British committee for standards in haematology. British Journal of Haematology 2008;140:496-504. [CrossRef] [PubMed] [Google Scholar]
  62. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS, COMMIT collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infaction : randomised placebo-controlled trial. Lancet 2005;366(9497): 1607-21. [CrossRef] [PubMed] [Google Scholar]
  63. Cocero N, Mozzati M, Ambrogio M, Bisi M, Morello M, Bergamasco L. Bleeding rate during surgery of oral anticoagulant therapy patients with associated systemic pathologic entities: a prospective study of more than 500 extractions. J Oral Maxillofac Surg 2014;72:858-67. [CrossRef] [PubMed] [Google Scholar]
  64. Collet JP, Himbert F, Steg PG. Myocardial infaction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol 2000;76:257-8. [CrossRef] [PubMed] [Google Scholar]
  65. Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard JL, Choussat R, Beygui F, Payot L, Vignolles N, Metzger JP, Thomas D. Impact of prior use or recent withdrawing of oral antiplatelet agents on acute coronary syndromes. Circulation 2004;110:2361-7. [CrossRef] [PubMed] [Google Scholar]
  66. Conan M, Massot M, Clipet F, Alno N, Lejeune S, De Mello G. Étude du rapport coût/sécurite lors de la prise en charge des patients sous antivitamines K en chirurgie buccale. Med Buccale Chir Buccale 2009;15:17-30. [CrossRef] [EDP Sciences] [Google Scholar]
  67. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J et al. Dabigatran versus warfarin in patient with atrial fibrillation. N Engl J Med 2009;361:1139-51. [CrossRef] [PubMed] [Google Scholar]
  68. Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17. [CrossRef] [PubMed] [Google Scholar]
  69. Cooke GE, Liu-Sratton Y, Kerketich AK et al. Effect of platelet antigen polymorphism on plaqtelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol 2006;47:541-6. [CrossRef] [PubMed] [Google Scholar]
  70. Cosmi B, Alatri A, Cattaneo M, Gresele P, Marrieta M, and Italian Society for Haesmostasis and Thrombosis. Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures. Guidelines. Thromb Res 2009;124(5):e6-e12. [CrossRef] [PubMed] [Google Scholar]
  71. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008; 111:4871-9. [CrossRef] [PubMed] [Google Scholar]
  72. Czembireck C, Poeschl WP, Eder-Czembirek C, Fischer MB, Perisanidis C, Jesch Ph,Schicho K, Dong A, Seemann R. Causes and timing of delayed bleeding after oral surgery. Clin Oral Invest 2014;18:1655-61. [CrossRef] [Google Scholar]
  73. Daïmellah F, Issad MS, Boukaïs H, Zerrouki W, Berkane M, Lehachi S, Bennoui Z, Khellil S, Hannoun D, Abrouk S. Avulsions dentaires chez les patients cardiaques traités par anticoagulants : résultats d'un essai thérapeutique acénocoumarol versus héparine calcique. Med Buccale Chir Buccale 2009;15:63-74. [CrossRef] [EDP Sciences] [Google Scholar]
  74. Daïmellah F, Issad MS, Lehachi S, Bennoui Z, Khelil S, Boukaïs H, Zerrouki W, Berkane M, Hannoun D, Abrouk S. Facteurs de risque hémorragique chez les patients sous antivitamine K en chirurgie buccale. Med Buccale Chir Buccale 2010;16:209-15. [CrossRef] [EDP Sciences] [Google Scholar]
  75. Darriba MA, Mendonça-Caridad JJ. Profuse bleeding and life-threatening airway obstruction after placement of mandibular dental implants. J Oral Maxillofac Surg 1997;55:1328-30. [CrossRef] [PubMed] [Google Scholar]
  76. Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, Fox KA, Montalescot G, Weber MA, Haffner SM, Dimas AP, Steg PG, Topol EJ, CHARISMA Investigators. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance trial. Am J Cardiol. 2009;103:1359-63. [CrossRef] [PubMed] [Google Scholar]
  77. Davis C, Robertson C, Shivakumar S, Lee Min. Implications of dabigatran, a direct thrombin inhibitor, for oral surgery practice. J Can Dent Asooc 2013;7979:d74:1-7. [Google Scholar]
  78. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-94. [CrossRef] [PubMed] [Google Scholar]
  79. Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother 2003;37:367-70. [CrossRef] [PubMed] [Google Scholar]
  80. Degirmenci SE, Steib A. Les anticoagulants dans la prevention de la thrombose veineuse. Rev Prat 2013;63:976-9. [PubMed] [Google Scholar]
  81. Desmard M, Hellmann R, Plantefève G, Mentec H. Surdosage grave en antivitamine K secondaire à l’absorption de jus de pamplemouse. Ann Fr Anesth Reanima 2009;28:897-9. [CrossRef] [Google Scholar]
  82. Devani P, Lavery KM, Howell CJT. Dental extractions in patients on warfarin: is alteration of anticoagulant regime necessary ? Br J Oral Maxillofac Surg 1998;36:107-11. [CrossRef] [PubMed] [Google Scholar]
  83. Doonquah L, Mitchell AD. Oral surgery for patients on anticoagulant therapy: current thoughts on patient management. Dent Clin North Am 2012;56:25-41. [CrossRef] [PubMed] [Google Scholar]
  84. Douketis JD, Johnson JA, Turpie AG. Low-molecular - weight heparins bridging anticoagulation during interruption of warfarin assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004;164:1319-26. [CrossRef] [PubMed] [Google Scholar]
  85. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J, American College of Chest Physicians. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:299S-339S. [CrossRef] [PubMed] [Google Scholar]
  86. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J, American College of Chest Physicians. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). Chest. 2012;141:e326S-e350S. [CrossRef] [PubMed] [Google Scholar]
  87. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Thromb Haemost 2012;107:985-97. [CrossRef] [PubMed] [Google Scholar]
  88. Ducroq G, Steg PG. The role of new antiplatelet agents in the therapeutic stategy. Arch Cardiovascular Dis Suppl. 2012;4:195-9. [CrossRef] [Google Scholar]
  89. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999;57:1005-32. [CrossRef] [PubMed] [Google Scholar]
  90. Eerenberg ES, Kampuhuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573-9. [CrossRef] [PubMed] [Google Scholar]
  91. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141 (2 Suppl): e89S-119S. [CrossRef] [PubMed] [Google Scholar]
  92. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510. [CrossRef] [PubMed] [Google Scholar]
  93. EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366: 1287-97. [CrossRef] [PubMed] [Google Scholar]
  94. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Chritiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR. Oral Dabigatran etexilate versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5 (11):2178-85. [CrossRef] [PubMed] [Google Scholar]
  95. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial (RE-NOVATE I). Lancet 2007;370:949-56. [CrossRef] [PubMed] [Google Scholar]
  96. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlofer E, Misselwitz F, Geertz W. Rivaroxaban versus enoxaparin for thrombophylaxis after hip arthroplasty (RECORD 1). N Engl J Med. 2008;358:2765-75. [CrossRef] [PubMed] [Google Scholar]
  97. Eriksson BI, Smith H, Yasothan U, Kirkpatrick P. Dabigatran etexilate. Nat Rev Drug Discov 2008;7:557-8. [CrossRef] [PubMed] [Google Scholar]
  98. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011;105(4):721-9. [CrossRef] [PubMed] [Google Scholar]
  99. Evans IL, Sayers MS, Gibbons AJ, Price G, Snooks H, Sugar AW. Can warfarin be continued during dental extraction ? Results of a randomized controlled trial. Br J Oral Maxillofac 2002;40: 248-52. [CrossRef] [PubMed] [Google Scholar]
  100. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009;157:805-10. [CrossRef] [PubMed] [Google Scholar]
  101. Fakhri HR, Janket SJ, Jackson EA, Baird AE, Dinnocenzo R, Meurman JH. Tutorial in oral antithrombotic therapy: biology and dental implications. Med Oral Patol Oral Cir Bucal 2013;18: e461-72. [CrossRef] [PubMed] [Google Scholar]
  102. Ferrari E, Benhamou M, Cerboni P, Baudouy M. Coronary syndromes following aspirin withdrawal. Chest 2003;124:148S. [Google Scholar]
  103. Ferrari E, Benhamou M, Cerboni P, Baudouy M. Coronary syndromes following aspirin withdrawal. A special risk for late stent thrombosis. J Am Coll Cardiol 2005;45:456-9. [CrossRef] [PubMed] [Google Scholar]
  104. Ferrieri GB, Castiglioni S, Carmagnola D, Cargnel M, Strohmenger L, Abati S. Oral surgery in patients on anticoagulant treatment without therapy interruption. J Oral Maxillofac Surg 2007;65: 1149-54. [CrossRef] [PubMed] [Google Scholar]
  105. Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:431-41. [CrossRef] [PubMed] [Google Scholar]
  106. Fugh-Berman A. herb-drug interactions. Lancet 2000;355:134-8. [CrossRef] [PubMed] [Google Scholar]
  107. Funayama M, Kumagai T, Saito K, Watanabe T. Asphyxial death caused by postextraction hematoma. Am J Forensic Med Pathol 1994;15:87-90. [CrossRef] [PubMed] [Google Scholar]
  108. Gagneja M, Gagneja P, Steelman R, Shaughnessy R, Johannes PW. Oral surgery in a child with a prosthetic aortic valve and pulmonary artery stent at risk for thromboembolism. J Clin Pediatr Dent 2008;32:151-3. [CrossRef] [PubMed] [Google Scholar]
  109. Gangloff P. Prise en charge des patients traités par agents antiplaquettaires et antivitamines k. In: Editions CdP WKF, editor: Manuel de chirurgie orale : Technique de réalisation pratique, maîtrise et exercice raisonné au quotidien. Collection JPIO ;2012:536 p. [Google Scholar]
  110. Garcia DA, Regan S, Henault LE, Upadahyay A, Baker J, Othman M, Hylek EM. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008;168: 63-69. [CrossRef] [PubMed] [Google Scholar]
  111. Garcia DA, Baglin TP, Weitz JI, Samama MM, American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e24S-43S. [CrossRef] [PubMed] [Google Scholar]
  112. Garcia Rodriguez LA, Cea-Soriano L, Martin-Merino E. Discontinuation of low-dose aspirin and risk of myocardila infarction: cas-control study in UK primary care. Br Med J 2011;343:d4094. [CrossRef] [PubMed] [Google Scholar]
  113. Garnier J, Truchot F, Quero J, Meziere X, Clipet F, Alno N, Frachon X, Delanoue O, Bader G, Lejeune S, Limbour P, De Mello G. 218 tooth extraction in patients tacking platelet aggregation inhibitors. Rev Stomatol Chir Maxillofac 2007;108:407-10. [CrossRef] [PubMed] [Google Scholar]
  114. Gaspar R, Brenner B, Ardekian L, Peled M, Laufer D. Use of tranexamic acid mouthwash to prevent postoperative bleeding in oral surgery patients on oral antcoagulant medication. Quintessence Int 1997;28:375-9. [PubMed] [Google Scholar]
  115. Gaudy JF, Ankri A, Tager F, El Haddioui A,Bravetti P, Lafont A, Gogly B. Anticoagulants et extractions dentaires. Arch Mal Coeur Vaiss. 2005;98:859-66. [PubMed] [Google Scholar]
  116. Gerstein NS, Schulman PM, Gerstein WH, Petersen TR, Tawil I. Should more patients continue aspirin therapy perioperatively? Clinical impact of aspirin withdrawal syndrome. Ann Surg 2012;255(5):811-9. [CrossRef] [PubMed] [Google Scholar]
  117. Givol N, Chaushu G, Halamish-Shani T, Taicher S. Emergency tracheostomy following life-threatening hemorrhage in the floor of the mouth during immediate implant placement in the mandibular canine region. J Periodontol 2000;71:1893-5. [CrossRef] [PubMed] [Google Scholar]
  118. Gersel-Pedersen N. Fibrinolytic activity of blood an d saliva before and after oral surgery. Int J de Oral Surg 1981;10 (Suppl1):114-21. [Google Scholar]
  119. Graff J, von Hentig N, Misselwitz F, Kubitza D, Becka M, Breddin HK, Harder S. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007;47:1398-407. [CrossRef] [PubMed] [Google Scholar]
  120. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92. [CrossRef] [PubMed] [Google Scholar]
  121. Grines CL, Bonow RO, Casey Jr DE, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Dent Assoc 2007;138:652-655. [CrossRef] [PubMed] [Google Scholar]
  122. Groupe d’Étude sur l’Hemostase et de la Thrombose (GEHT). Prise en charge des surdosages, des situations à risque hémorragique et des accidents hémorragiques chez les patients traités par antivitamines K en ville et en milieu hospitalier. Recommandations pour la pratique clinique. Avril 2008. [Google Scholar]
  123. Groupe d’Étude sur l’Hémostase et de la Thrombose (GEHT). Rivaroxaban et test de biologie medicale. Octobre 2012. [Google Scholar]
  124. Groupe d’Étude sur l’Hémostase et de la Thrombose (GEHT). Héparine, dérivés hépariniques et antagonistes de la vitamine K. Maniement, surveillance biologique, gestions des complications. Décembre 2012. [Google Scholar]
  125. Guyat GH, Akl EA, Crowther M, Gutterman DD, Schünemann HJ. Antithrombotic therapy and prevention of thrombosis (9th ed).American College of Chest Physicians. Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl):7S-47S. [CrossRef] [PubMed] [Google Scholar]
  126. Halfpenny W, Fraser JS, Adlam DM. Comparison of 2 hemostatic agents for the prevention of postextraction hemorrhage in patients on anticoagulants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:257-9. [CrossRef] [PubMed] [Google Scholar]
  127. Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg 2011;112:292-318. [CrossRef] [PubMed] [Google Scholar]
  128. Harder S. Renal profiles of anticoagulants. J Clin Pharmacol 2012;52:964-75. [CrossRef] [PubMed] [Google Scholar]
  129. Hart RG, Benavente O, McBride R et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation : a meta-anlysis. Ann Intern Med 1999;131:492-501. [CrossRef] [PubMed] [Google Scholar]
  130. Haute Autorité de Santé (HAS). Commission de Transparence. Mini-sintrom 1mg, comprimé et Sintrom 4 mg, comprimé quadrisécable. Avis du 2 novembre 2005. [Google Scholar]
  131. Haute Autorité de Santé (HAS). Commission de Transparence. Feiba 500 UI/20ml, poudre et solvant pour solution injectable. Avis du 30 novembre 2005. [Google Scholar]
  132. Haute Autorité de Santé (HAS). Commission de Transparence. Persantine 75 mg, comprimé enrobé. Avis du 10 mai 2006. [Google Scholar]
  133. Haute Autorité de Santé (HAS). Commission de Transparence. Cardiosolupsan, poudre effervescente pour solution buvable. Avis du 19 juillet 2006. [Google Scholar]
  134. Haute Autorité de Santé (HAS). Commission de Transparence. Fraxodi et Fraxiparine, solution injectable SC en seringue préremplie avec système de sécurité. Avis du 18 octobre 2006. [Google Scholar]
  135. Haute Autorité de Santé (HAS). Commission de Transparence. Plavix 75 mg, comprimé pelliculé. Avis du 06 juin 2007. [Google Scholar]
  136. Haute Autorité de Santé (HAS). Commission de Transparence. Calciparine sous-cutanée, solution injectable. Avis du 23 janvier 2008. [Google Scholar]
  137. Haute Autorité de Santé (HAS). Commission de Transparence. Lovenox, solution injectable (sous-cutanée) en seingue préremplie. Avis du 2 avril 2008. [Google Scholar]
  138. Haute Autorité de Santé (HAS). Commission de Transparence. Héparine Choay 25 000UI/5ml, solution injectable (IV). Avis du 3 septembre 2008. [Google Scholar]
  139. Haute Autorité de Santé (HAS). Commission de Transparence.Efient 10mg, comprimé pelliculé. Avis du 22 juillet 2009. [Google Scholar]
  140. Haute Autorité de Santé (HAS). Commission de Transparence.Innohep, solution injectable (sous-cutanée) en seringue pré-remplie. Avis du 16 décembre 2009. [Google Scholar]
  141. Haute Autorité de Santé (HAS). Commission de Transparence. Duoplavin 75mg/75mg, comprimé pelliculé. Avis du 21 juillet 2010. [Google Scholar]
  142. Haute Autorité de Santé (HAS). Commission de Transparence. Asasantine LP 200mg/ 25mg, gélule à libération prolongée. Avis du 15 décembre 2010. [Google Scholar]
  143. Haute Autorité de Santé (HAS). Commission de Transparence. Pravadual, comprimé. Avis du 2 février 2011. [Google Scholar]
  144. Haute Autorité de Santé (HAS). Commission de Transparence. Previscan 20 mg, comprimé quadrisécable. Avis du 20 juillet 2011. [Google Scholar]
  145. Haute Autorité de Santé (HAS). Commission de Transparence. Kardégic 75 mg, 160 mg, 300 mg, poudre pour solution buvable en sachet dose. Avis du 21 septembre 2011. [Google Scholar]
  146. Haute Autorité de Santé (HAS). Commission de Transparence. Brilique 90 mg, comprimé pelliculé. Avis du 7 décembre 2011. septembre 2011. [Google Scholar]
  147. Haute Autorité de Santé (HAS). Commission de Transparence. Coumadine 2 mg, 5 mg, comprimé sécable. Avis du 1er fevrier 2012. [Google Scholar]
  148. Haute Autorité de Santé (HAS). Commission de Transparence. Pradaxa 110mg, 150 mg, comprimé pelliculé. Avis du 14 mars 2012 [Google Scholar]
  149. Haute Autorité de Santé (HAS). Commission de Transparence. Xarelto 15 mg, 20 mg, gélules. Avis du 29 février 2012. [Google Scholar]
  150. Haute Autorité de Santé (HAS). Commission de Transparence.Ticlid 250mg, comprimé pélliculé. Avis du 11 avril 2012. [Google Scholar]
  151. Haute Autorité de Santé (HAS). Commission de Transparence. Exacyl 1g/ 10 ml, solution buvable. Avis du 12 juin 2013. [Google Scholar]
  152. Haute Autorité de Santé (HAS). Commission de Transparence. Eliquis 2,5mg, 5 mg, comprimé pellicullé. Avis du 12 juin 2013. [Google Scholar]
  153. Haute Autorité de Santé (HAS). Commission de Transparence. Fragmine, solution injectable, seringue préremplie. Avis du 22 janvier 2014. [Google Scholar]
  154. Haute Autorité de Santé (HAS). Guide du médecin- Affection de longue durée- Maladie coronarienne. mars 2007. [Google Scholar]
  155. Haute Autorité de Santé (HAS). Guide du médecin- Affection de longue durée- Accident vasculaire cérébral. mars 2007. [Google Scholar]
  156. Haute Autorité de Santé (HAS). Guide du médecin- Affection de longue durée- Artériopathie oblitérante des membres inférieurs. mars 2007. [Google Scholar]
  157. Haute Autorité de Santé (HAS). Guide du médecin- Affection de longue durée- Fibrillation auriculaire. juillet 2007. [Google Scholar]
  158. Haute Autorité de Santé (HAS). Guide du médecin- Affection de longue durée- Cardiopathies valvulaires et congénitales graves chez l’adulte. juin 2008. [Google Scholar]
  159. Haute Autorité de Santé (HAS). Indicateurs de pratique clinique et indicateurs d’alerte et de maîtrise de la iatrogénie. Contrôle de l’INR si AVK et introduction d’un antibiotique ou d’un antifongique. Octobre 2012. [Google Scholar]
  160. Haute Autorité de Santé (HAS). Rapport d’évaluation technologique. Hémostatiques chirurgicaux. Juin 2011. [Google Scholar]
  161. Haute Autorité de Santé (HAS). Rapport d’évaluation technologique. Biologie des anomalies de l’hémostase. Tome 1 : temps de saignement (Epreuve de Duke et tests d’Ivy). Juillet 2011. [Google Scholar]
  162. Haute Autorités de Santé (HAS). Recommandations de bonne pratique. Antiagrégants plaquettaires : prise en compte des risques thrombotique et hémorragique en cas de geste endoscopique chez le coronarien. Méthode Recommandation par consensus formalisé. Juin 2012. [Google Scholar]
  163. Haute Autorité de Santé (HAS). Recommandation de bonne pratique. Antiagrégants plaquettaires : prise en compte des risques thrombotique et hémorragique pour les gestes percutanés chez le coronarien. Méthode Recommandation par consensus formalisé. Novembre 2013. [Google Scholar]
  164. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M, RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RELY) randomized trial. Circulation 2012;126:343-8. [CrossRef] [PubMed] [Google Scholar]
  165. Ho M, Peterson E, Wang L et al. Incidence of death and acute muocardial infarctus associated with stopping clopidogrel after acute coronary syndrome. J Am Med Assoc 2008;299:532-9. [CrossRef] [PubMed] [Google Scholar]
  166. Ho M, Tsai T, Wang T et al. Adverse events after stopping clopidogrel in post-acute coronary syndrome patients. Insights from a large integrated healthcare delivery system. Cir Cardiovasc Qual Outcomes 2010;3:303-8. [CrossRef] [Google Scholar]
  167. Hong CH, Napeñas JJ, Brennan MT, Furney SL, Lockhart PB. Frequency of bleeding following invasive dental procedures in patients on low-molecular-weight heparin therapy. J Oral Maxillofac Surg 2010;68:975-9. [CrossRef] [PubMed] [Google Scholar]
  168. Hong C, Napeñas JJ, Brennan M, Furney S, Lockhart P. Risk of postoperative bledding after dental procedures in patients on warfarin: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2012;114:464-8. [CrossRef] [Google Scholar]
  169. Hong YH, Mun SK. A case of massive maxillary sinus bleeding after dental implant. Int J Oral Maxillofac Surg 2011;40:758-60. [CrossRef] [PubMed] [Google Scholar]
  170. Hughes GJ, Patel PN, Saxena N. Acetaminophen on International Normalized Ratio in patients receiving warfarin therapy. Pharmacotherapy 2011;31:591-7. [CrossRef] [PubMed] [Google Scholar]
  171. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998;279:657-62. [CrossRef] [PubMed] [Google Scholar]
  172. Iung B. Extractions dentaires sous anticoagulants: améliorer la prise en charge par une approche multidisciplinaire. Arch Mal Coeur Vaiss. 2005;98:857-8. [PubMed] [Google Scholar]
  173. Iwabuchi H, Imai Y, Asanami S, Shirakawa M, Yamane GY, Ogiuchi H, Kurashina K, Miyata M, Nakao H, Imai H. Evaluation of postextaction bleeding incidence to compare patients receiving and not receiving warfarin therapy: a cross-sectional, multicenter, observational study. BMJ Open 2014;4:e005777. Doi10.1136/bmjopen-2014-005777. [CrossRef] [PubMed] [Google Scholar]
  174. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157:599-605. [CrossRef] [PubMed] [Google Scholar]
  175. Jensen SS, Eriksen J, Schiodt M. Severe bleeding after sinus floor elevation using the transcrestal technique: a case report. Eur J Oral Implantol 2012;5:287-291. [PubMed] [Google Scholar]
  176. Johnson-Leong C, Rada RE. The use of low-molecular-weight heparins in out patient oral surgery for patients receiving anticoagulation therapy. J Am Dent Assoc 2002;133:1083-7. [CrossRef] [PubMed] [Google Scholar]
  177. Journal Officiel de la République Française. Décision du 11 février 2013 de l’Union nationale des caisses d’assurance maladie relative à la liste des actes et prestations pris en charge par l’assurance maladie « sous-chapitre 5-02 _Hémostase et coagulation ». [Google Scholar]
  178. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Akos F, Misselwitz F, Hass S. Extensed duration rivaroxaban versus short term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-bind randomized controlled trial (RECORD 2). The Lancet 2008;372 (9632):31-39. [Google Scholar]
  179. Kalpidis CD, Konstantinidis AB. Critical hemorrhage in the floor of the mouth during implant placement in the first mandibular premolar position: a case report. Implant Dent 2005;14:177-84. [CrossRef] [Google Scholar]
  180. Karsh ED, Erdogan Ö, Esen E, Acartürk E. Comparison of the effects of warfarin and heparin on bleeding caused by dental extraction: a clinical study. J Oral Maxillofac Surg 2011; 69:2500-7. [CrossRef] [PubMed] [Google Scholar]
  181. KeianiMotlagh K, Loeb I, Legrand W, Daelemans P, van Reck J. Prévention des saignements postopératoires chez des patients sous anticoagulants oraux. Effets de l’acide tranexamique. Rev Stomatol Chir Maxillofac 2003;104:77-9. [PubMed] [Google Scholar]
  182. Kinnby B, Lindberg P, Lecander I, Matsson L. Localization of plasminogen activators and plasminogen-activator inhibitors in human gingival tissues demonstrated by immunohistochemistry and in situ hybridization. Arche Oral Biol 1999;44:1027-1034. [CrossRef] [Google Scholar]
  183. Kosyfaki P, Att W, Strub JR. The dental patient on oral anticoagulant medication: a literature review. J Oral Rehabil. 2011;38:615-33. [CrossRef] [PubMed] [Google Scholar]
  184. Kovacs MJ, Kearon C, Rodger M, Anderson DR, Turpie AG, Bates MD, Desjardins L, Doukertis MD, Kahn SR, Solymoss S, Wells PS. Single –arm of study of briding therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004;110: 1658-63. [CrossRef] [PubMed] [Google Scholar]
  185. Krishnan B, Sheny NA, Alexander M. Exodontia and antiplatelet therapy. J Oral Maxillofac Surg 2008;66:2063-6. [CrossRef] [PubMed] [Google Scholar]
  186. Laboda G. Life-threatening hemorrhage after placement of an endosseous implant: report of case. J Am Dent Assoc 1990;121: 599-600. [CrossRef] [PubMed] [Google Scholar]
  187. Lane MA, Devine ST, Mc Donald JR. High-risk antimicrobial prescriptions among ambulatory patients on warfarin.J Clin Pharmacy Therap 2011: doi:10.1111/j.1365-2710.2011.01270.x [Google Scholar]
  188. Larsen TR, Gelaye A, Durando C. Acute warfarin toxicity: an unanticipated consequence of amoxicillin/clavulanate administration. Am J Case Rep 2014;15:45-8. [CrossRef] [PubMed] [Google Scholar]
  189. Lassen MR, Ageno W, Lars C, Borris MD, Jay R, Liberman MB, Rosencher N, Tiemo J, Bandel MD, Missewitz F, Turpie AG. Rivaroxaban versus enoxaparin for thrombophylaxis after total knee arthroplasty (RECORD 3). N Eng J Med 2008;358:2776-86. [CrossRef] [PubMed] [Google Scholar]
  190. Lega JC, Bertoletti L, Durupt S, Epinat M, Mismetti P, Da Costa A. Nouveaux anticoagulants oraux dans la fibrillation atriale non valvulaire. La Presse Médicale, 2013;42(9):1225-31. [CrossRef] [Google Scholar]
  191. Le Heuzey JY, Marijon E, Lepillier A, Fiorina L, Charlemagne A, Lavergne T, Pornin M. La fibrillation atriale : données démographique. www.réalitéscardiologiques.com/wp-contenu/uploads/2010/03/10.pdf. (page consulté le 05.01.2014). [Google Scholar]
  192. Leonardi-Bee J, Bath PM, Bousser MG, Davalos A, Diener HC, Guiraud-Chaumeil B, Sivenius J, Yatsu F, Dewey ME. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: A meta-analysis of individual patient data from randomized controlled trials. Stroke. 2005;36:162-8. [CrossRef] [PubMed] [Google Scholar]
  193. Lesca C, Boumendjel S, Boumendjel M, Hefied M, Ben Ismail S,Bonnefous D. Local haemostasis with an adhesive cyano-coated membrane following tooth extraction in patients under anticoagulant or antiplatelet therapy. Rev Stomatol Chir Maxillofac 2012;113:143-7. [CrossRef] [PubMed] [Google Scholar]
  194. Levi MM, Eerenberg E, Lowenberg E, Kamphuisen PW. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010;68:68-76. [PubMed] [Google Scholar]
  195. Lev-Ran O, Kramer A, Gurevitch J. Low-molecular weight heparin for prosthetic heart valves. Ann Thorac Surg 2000;69:264. [CrossRef] [PubMed] [Google Scholar]
  196. Lewis BS, Mehta SR, Fox KA, Halon DA, Zhao F, Peters RJ, Keltai M, Budaj A, Yusuf S, CURE trial investigators. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events study. Am Heart J 2005;150 (6):1177-84. [CrossRef] [PubMed] [Google Scholar]
  197. Lillis T, Ziakas A, Koskinas K, Tsirlis A, Giannoglou G. Safety of dental extractions during uninterrupted single or dual antiplatelet treatment. Am J Cardiol 2011;108:964-7. [CrossRef] [PubMed] [Google Scholar]
  198. Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991;77(12):2547-52. [PubMed] [Google Scholar]
  199. Lockhart PB, Gibson J, Pond SH, Leicht J. Dental management considerations for the patient with an acquired coagulopathy. Part 1: coagulopathies from systemic disease. Br Dent J 2003;195:439-45. [CrossRef] [PubMed] [Google Scholar]
  200. Lopes RD, Horowitz JD, Garcia DA, Crowther MA, Hylek EM. Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. Blood 2011;118:62769-73. [CrossRef] [Google Scholar]
  201. Lordkipanidze M, Diodati JG, Pharand Ch. Possibility of a rebound phenomenon following antiplatelet therapy withdrawal : a look at the clinical and pharmacological evidence. Pharmacology and Therapeutics 2009;123:178-85. [CrossRef] [PubMed] [Google Scholar]
  202. Lowry JC. Thromboembolic disease and thromboprophylaxis in oral and maxillofacial surgery. Experience and practice. Br J Oral Maxillofac Surg 1995;33:101-6. [CrossRef] [PubMed] [Google Scholar]
  203. Mac Donalds TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573-4. [CrossRef] [PubMed] [Google Scholar]
  204. Madan GA, Madan SG, Madan G, Madan AD. Minor oral surgery without stopping daily low-dose aspirin therapy: a study of 51 patients. J Oral Maxillofac Surg 2005;65:1262-5. [CrossRef] [Google Scholar]
  205. Madrid C, Sanz M. What influence do anticoagulants have on oral implant therapy ? A systematic review. Clin Oral Implants Res 2009;20:96-106. [CrossRef] [Google Scholar]
  206. Mahe I, Bertrand N, Drouet L, Bal Di SollierCl, Simoneau G, Mazoyer E, Caulin Ch, Bergmann JF. Intercation between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study. Haematologica 2006;91:1621-7. [PubMed] [Google Scholar]
  207. Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M, Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematology 2012;160:35-46. [CrossRef] [Google Scholar]
  208. Malden NJ, Santini A, Mather CI, Gardner A. Minor oral surgery and interference with anticoagulation in patients taking warfarin: a retrospective study. Br J Oral Maxillofac Surg 2007;45: 645-7. [CrossRef] [PubMed] [Google Scholar]
  209. Martinowitz U, Mazr AL, Taicher S, Varon D, Gitel SN, Ramot B, Rakocz M. Dental extraction for patients on oral anticoagulant therapy. Oral Surg Oral Med Oral Pathol 1990;70:274-7. [CrossRef] [PubMed] [Google Scholar]
  210. Mas JL. Atrial fibrillation: thromboembolic complications. Arch Cardio Dis Suppl 2013;5:125-31. [Google Scholar]
  211. Masson ME, Triplet RG, Alfonso WF. Life-threatening hemorrhage from placement of a dental implant. J Oral Maxillofac Surg 1990;48:201-4. [CrossRef] [PubMed] [Google Scholar]
  212. Medeiros FB, de Andrade AC, Angelis GA, Conrado VC, Timerman L, Farsky P, Dib LL. Bleeding evaluation during single tooth extraction in patients with coronary artery disease and acetylsalicylic acid therapy suspension : a prospective, double-blinded, and randomized study. J Oral Maxillofac Surg 2011;69:2949-55. [CrossRef] [PubMed] [Google Scholar]
  213. Mehta SR, Yusuf S, Clopidogrel in Unstable angina to prevent Recurrent Events Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000;21:2033-41. [CrossRef] [PubMed] [Google Scholar]
  214. Michel P. L’arrêt de l’aspirine augmente le risqué de récidive d’accident vasculaire cerebral. 30th International Stroke Conference. Stroke 2005;36:416 (abstract). [Google Scholar]
  215. Michelson AD. New P2Y12 antagonists. Curr Opin Hematol 2009;16:371-7. [CrossRef] [PubMed] [Google Scholar]
  216. Minassian C, D’Aiuto F, Hingorani AD, Smeeth L. Invasive dental treatment and risk for vascular events: a self-controlled cases series. Ann Intern Med 2010;153:499-506. [CrossRef] [PubMed] [Google Scholar]
  217. Mismetti P, Laporte S. Rivaroxaban: clinical pharmacology. Ann Fr Anesth Rea 2008;27:S16-S21. [CrossRef] [Google Scholar]
  218. Moghadam HG, Caminiti MF. Life-threatening hemorrhage after extraction third molars: case report and management protocol. J Can Dent Assoc 2002;68:670-4. [PubMed] [Google Scholar]
  219. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM, TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723-31. [CrossRef] [PubMed] [Google Scholar]
  220. Mordenfeld A, Andersson L, Bergström B. Hemorrhage in the floor of the mouth during implant placement in the edentulous mandible: a case report. Int J Oral Maxillofac Implants 1997;12: 558-561. [PubMed] [Google Scholar]
  221. Moreira P, Filho PM, Silva EA, Weksler C, Drable SG, Tura BR, Fonseca Mda G, Cunha AB, Fischer RG. Effect of periodontal treatment on oral anticoagulation in patients with heart disease. Rev Port Cardiol. 2007;26:977-89. [PubMed] [Google Scholar]
  222. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M, Escaned J, Banuelos C, Fernandez-Ortiz A, Macaya C. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954–9. [CrossRef] [PubMed] [Google Scholar]
  223. Morimoto Y, Niwa H, Minematsu K. Hemostatic management of tooth extractions in patients on oral antithrombotic therapy. J Oral Maxillofac Surg. 2008a;66:51-7. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  224. Morimoto Y, Niwa H, Hanatani A, Nakatani T. Hemostatic management during oral surgery in patients with a left-ventricular assist system undergoing high-level anticoagulant therapy: efficacy of low molecular weight heparin. J Oral Maxillofac Surg. 2008b;66:568-71. [CrossRef] [PubMed] [Google Scholar]
  225. Morimoto Y, Niwa H, Minematsu K. Risk factors affecting postoperative hemorrhage after tooth extraction in patients receiving oral antithrombotic therapy. J Oral Maxillofac Surg 2011;69:1550-6. [CrossRef] [PubMed] [Google Scholar]
  226. Morimoto Y, Niwa H, Minematsu K. Risk factors affecting hemorrhage after tooth extraction in patients undergoing continuous infusion with unfractionated heparin. J Oral Maxillofac Surg. 2012;70:521-6. [CrossRef] [PubMed] [Google Scholar]
  227. Napenas JJ, Hong CH, Brennan MT, Furney SL, Fox PC, Lockhart PB. The frequency of bleeding complications after invasive dental treatment in patients receiving single and dual antiplatelet therapy. J Am Dent Ass 2009;140:690-5. [CrossRef] [PubMed] [Google Scholar]
  228. Napenas JJ, Oost FC, de Groot A, Loven B, Hong CH, Brennan MT, Lockhart PB, van Dierman DE. Review of postoperative bleeding risk in dental patients on antiplatelet therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115:491-9. [CrossRef] [PubMed] [Google Scholar]
  229. Nematullah A, Alabousi A, Blanas N, Douketis JD, Sutherland SE. Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis. J Can Dent Assoc. 2009;75:41-41i. [PubMed] [Google Scholar]
  230. Niamtu J. Near-fatal airway obstruction after routine implant placement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:597-600. [CrossRef] [PubMed] [Google Scholar]
  231. Nizamaldin Y, Abi Najm S, El Hage M,Samson J. Hémostase locale en chirurgie orale. 1ère partie : physiologie de l’hémostase. Med Buccale Chir Buccale 2012a;18:119-127. [CrossRef] [EDP Sciences] [Google Scholar]
  232. Nizamaldin Y, Samson J. Hémostase locale en Chirurgie orale. 2ème partie : efficacité de la colle de fibrine. Med Buccale Chir Buccale 2012b;18:193-210. [CrossRef] [EDP Sciences] [Google Scholar]
  233. Oger E. Incidence of venous thromboembolism: A community-based study in western France. Epi-getbp study group. Groupe d’étude de la thrombose de bretagne occidentale. Thromb Haemost. 2000;83:657-60. [CrossRef] [PubMed] [Google Scholar]
  234. Olmos-Carrasco O, Pastor-Ramos V, Espinilla-Blaco R, Ortiz-Zarate A, Garcia-Avilla I, Rodriguez-Alonso E, Herrero-Sanjuan R, Ruiz-Garcia MM, Gallego-Beuter P, Sanchez-Salgado MP, Teran-Augustin AI, Fernandez-Behar M, Pena-Sainz I. Hemorrhagic complications of dental extractions in 181 patients undergoing double antiplaqtelet therapy. J Oral Maxillofac Surg 2015;73: 203-10. [CrossRef] [PubMed] [Google Scholar]
  235. Panula K, Oikarinen K. Severe hemorrhage after implant surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;87 (1):2. [CrossRef] [PubMed] [Google Scholar]
  236. Patatanian E, Fugate SE. Hemostatic mouthwashes in anticoagulated patients undergoing dental extraction. Ann Pharmacother. 2006;40:2205-10. [CrossRef] [PubMed] [Google Scholar]
  237. Patridge CG, Campbell JH, Alvarado F. The effect of platelet-altering medications on bleeding from minor oral surgery procedures. J Oral Maxillofac Surg 2008;66:93-7. [CrossRef] [PubMed] [Google Scholar]
  238. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, (ROCKET AF Investigators). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91. [CrossRef] [PubMed] [Google Scholar]
  239. Park MW, Her SH, Kwon JB, Lee JB, Choi MS, Cho JS et al. Safety of dental extractions in coronary drug-eluting stenting patients without stopping multiple antiplatelet agents. Clin Cardiol 2012;35:225-30. [CrossRef] [PubMed] [Google Scholar]
  240. Payne DA, Hayes PD, Jones CI, Belham P, Naylor AR, Goodall AH. Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action. J Vasc Surg 2002;35:1204-9. [CrossRef] [PubMed] [Google Scholar]
  241. -Penning van Best FJ, van Meegen E, Rosendaal FR, Stricker BH. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther 2001;69:451-7. [CrossRef] [PubMed] [Google Scholar]
  242. Pettinger TK, Owens CT. Use of low-molecular-weight heparin during dental extractions in a medicaid population. J Manag Care Pharm. 2007;13:53-8. [PubMed] [Google Scholar]
  243. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Schved JF, de Maiste E, Samama MM, Sié P. Prise en charge des complications hémorragiques graves et de la chirurgie en urgence chez des patients recevant un anticoagulat oral anti-IIa ou anti-Xa direct. Propositions du Groupe d’Intérêt en Hémostase Périopératoire (GIHP)-mars 2013. Ann Fr Anesth Reanim 2013 ; http://dx.doi.org/10.1016/j.annfar.2013.04.016 [Google Scholar]
  244. Perry DJ, Noakes TJ, Helliwell PS, British Dental Society. Guidelines for the management of patients on oral anticoagulants requiring dental surgery. Br Dent J. 2007;203:389-93. [CrossRef] [PubMed] [Google Scholar]
  245. Persac S, Boland FX, Lavis JF, Tardif A. Avulsions dentaires et anticoagulants. Rev Stomatol Chir Maxillofac. 2007;108:189-92. [CrossRef] [PubMed] [Google Scholar]
  246. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (has-bled) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey. Chest 2010;138:1093-100. [CrossRef] [PubMed] [Google Scholar]
  247. Pototski M, Amenábar JM. Dental management of patients receiving anticoagulation or antiplatelet treatment. J Oral Sci. 2007;49:253-8. [CrossRef] [PubMed] [Google Scholar]
  248. Rai R, Mohan B, Pratap Singh V, Namita, Wander GS. The risk of bleeding during dental extractions in patients receiving antiplatelet therapy. Indian J Dental Sciences 2013;4 (5):016-018. [Google Scholar]
  249. Ramström G, Sindet-Pedersen S, Hall G, Blombäck M, Alander U. Prevention of Postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants. J Oral Maxillofac Surg 1993;51:1211-6 [CrossRef] [PubMed] [Google Scholar]
  250. Rodgers RP, Levin J. A critical reappraisal of bleeding time. Semin Thromb Hemost 1990;16:1-20. [CrossRef] [Google Scholar]
  251. Rossi ML, Zavalloni D, Gasparini GL, Presbitero P. Very late multivessel thrombosis of bare stents with concomitant patent drug-eluting stent after withdrawal of aspirin. Int J Cardiol 2008;131:e7-9. [CrossRef] [PubMed] [Google Scholar]
  252. Rossini R, Capodanno D. Prevalence predictors and long-term prognosis premature discontinuation of oral antiplatelet therapy after eluting stent implantation. Am J Cardiol 2011;107:186-94. [CrossRef] [PubMed] [Google Scholar]
  253. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation (CLARITY study). N Engl J Med 2005;352:1179-89. [CrossRef] [PubMed] [Google Scholar]
  254. Sacco R, Sacco M, Carpenedo M, Mannucci PM. Oral surgery in patients on oral anticoagulant therapy: a randomized comparison of different intensity targets. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:e18-21. [CrossRef] [Google Scholar]
  255. Salam S, Yusuf H, Milosevic A. Bleeding after dental extractions in patients taking warfarin. Br J Oral Maxillofac Surg. 2007;45: 463-6. [CrossRef] [PubMed] [Google Scholar]
  256. Samama MM, Conard J, Lillo-Le-Louët A. Accidents hémorragiques des nouveaux anticoagulants oraux et examens de coagulation. J Mal Vasc 2013;38:259-270. [CrossRef] [PubMed] [Google Scholar]
  257. Sambu N, Warner T, Curzen N. Clopidogrel withdrawal is there a « rebound » phenomenon ? Thromb Haemost 2011;105:211-20. [CrossRef] [PubMed] [Google Scholar]
  258. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism (RECOVER study). New Eng J Med 2009;361:2342-52. [CrossRef] [PubMed] [Google Scholar]
  259. Sié P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, van der Linden P, Pernod G, Lecompte T, Gouin-Thibault I, Albaladejo P. Chirurgies et actes invasifs chez les patients traités au long cours par un anticoagulant oral anti-Iia ou anti-Xa direct. Propositions du groupe d’intérêt en hémostase périopératoire (GIHP) et du groupe d’études sur l’hémostase et la thrombose (GEHT). Ann Fr Anesth Reanim 2011a;30:645-50. [CrossRef] [PubMed] [Google Scholar]
  260. Sié P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, Van der Linden P, Pernod G, Lecompte T, Gouin-Thibault I, Albaladejo P, Working Group on Perioperative Haemostasis; French Study Group on Thrombosis and Haemostasis. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis 2011b;104:669-76. [CrossRef] [PubMed] [Google Scholar]
  261. Siguret V, Esquirol C, debray M, Gouin I, Andreux JP, Pautas E. Surdosages en antivitamine K dans une population de patients hospitalisés âgés de plus de 70 ans. Enquête prospective sur un an. Press Med 2003;32:972-7. [Google Scholar]
  262. Simonet V, Cambus JP, Léger P, Boneu B. Antivitamines K : utilisation pratique. Encyclopédie Médico-chirurgicale, 2003 13-022-D-50. [Google Scholar]
  263. Sindet-Pedersen S, Ramström G, Bernil S, Blombäck M. Hemostatic effect of tranexamic acid mouthwash in anticoagulant treated patients undergoing oral surgery. N Engl J Med 1989;320: 840-3. [CrossRef] [PubMed] [Google Scholar]
  264. Société française d’Anesthésie et de Réanimation (Sfar). Prévention de la maladie thromboembolique veineuse périopératoire et obstétricale. Recommandations pour la pratique clinique [en ligne]. 2005: http://www.sfar.org/t/spip.php,article270 [Google Scholar]
  265. Société française d’Anesthésie et de Réanimation (Sfar). Examens pré interventionnels systématiques. 13 janvier 2012. [Google Scholar]
  266. Société Francophone de Médecine Buccale et Chirurcie buccale (SFMbCb). Recommandations pour la prise en charge des patients sous agents antiplaquettaires en odontostomatologie. Med Buccale Chir Buccale 2005;11;2:55-76 [Google Scholar]
  267. Société francophone de Médecine Buccale et Chirurcie buccale (SFMbCb). Recommandations pour la prise en charge des patients sous traitement anti-vitamines k en chirurgie bucco-dentaire. Med Buccale Chir Buccale 2006;188-212. [Google Scholar]
  268. Soto J, Sacristan JA, Fernandez-Viadero C, Verduga R. Probable acenocoumarol-amoxycillin interaction. Acta Haematol 1993;90: 195-7. [CrossRef] [PubMed] [Google Scholar]
  269. Souto JC, Oliver A, Zuazu-Jausoro I, Vives A, Fontcuberta J. oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant: a prospective randomized study. J Oral Maxillofac Surg 1996;54:27-32. [CrossRef] [PubMed] [Google Scholar]
  270. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug—eluting stent placement. Results from the PREMIER registry. Circulation 2006;113;2803-9. [CrossRef] [PubMed] [Google Scholar]
  271. Spolarich AE, Andrews L. An examination of the bleeding complications associated with herbal supplements, antiplatelet and anticoagulant medications. J Dent Hyg. 2007;81:67. [PubMed] [Google Scholar]
  272. Spyropoulos AC, Turpie AGG, Spandorfer J. Clinical outcomes with unfractionated heparin or low-molecular –weight heparin as bridging therapy in patients on long-term oral anticoagulants: The REGIMEN Registry. J Thromb Haemost 2006;4:1246. [CrossRef] [PubMed] [Google Scholar]
  273. Spyropoulos AG, Turpie AGG, Dunn AS. Perioperative bridging therapy with unfractionned heparin or low-molecular weight heparin as bridging therapy in patients with mechanical prosthectic heart valves on long term oral anticoagulants (from the REGIMEN registry). Am J Cardiol 2008;102:883 [CrossRef] [PubMed] [Google Scholar]
  274. Spyropoulos AG., To bridge or not to bridge. That is the question. The argument for bridging therapy in patients on oral anticoagulants requiring temporary interruption for elective procedure. J Thromb Thrombolysis 2010;29:192. [CrossRef] [PubMed] [Google Scholar]
  275. Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, Niitsu Y, Asai F. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007;5:1545-51. [CrossRef] [PubMed] [Google Scholar]
  276. Todd W, Roman A. Outpatient use of Low-Molecular Weight Heparin in an anticoagulated patient requiring oral surgery: case report. J Oral Maxillofac Surg 2011;59:1090-2. [CrossRef] [Google Scholar]
  277. Václavík J, Táborský M. Antiplatelet therapy in the perioperative period. Eur J Intern Med 2011;22:26-31. [CrossRef] [PubMed] [Google Scholar]
  278. Van Diermen D, Aartman IHA, Baart JA, Hoogstraten J, van der Waal I. Dental management of patients using antithrombotic drugs critical appraisal of existing guidelines. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:616-24. [CrossRef] [PubMed] [Google Scholar]
  279. Van Ryn J, Strangler J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27. [CrossRef] [PubMed] [Google Scholar]
  280. Verma G, Tiwari AK, Chopra S. Aspirin and exodontias: a comparative study of the bleeding complications with aspirin therapy. International Journal of Dental Science and Research 2013;1:50-3. [CrossRef] [Google Scholar]
  281. Verma G. Dental extraction can be performed safely in patients on aspirin therapy: a timely reminder. ISRN Dentistry 2014, Article ID463684, http//:dx.dor.Org/10.1155/2014/463684. [Google Scholar]
  282. Vidal. Le dictionnaire. 2014;90e edition, Issy-les-Moulineau, France. www.vidal.fr [Google Scholar]
  283. Wahl MJ. Dental surgery and anticoagulated patients. Arch Intern Med 1998;158:1610-6. [CrossRef] [PubMed] [Google Scholar]
  284. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57. [CrossRef] [PubMed] [Google Scholar]
  285. Wittkowsky AK. Dietary supplements, herbs and oral anticoagulants: the nature of the evidence. J Thromb Thrombolysis 2008;25:72-77. [CrossRef] [PubMed] [Google Scholar]
  286. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15. [CrossRef] [PubMed] [Google Scholar]
  287. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, Luettgen JM, Knabb RM. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008;6:820-9. [CrossRef] [PubMed] [Google Scholar]
  288. Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 2011;31:478-92. [CrossRef] [PubMed] [Google Scholar]
  289. Wynn RL. Bleeding risks for older patients taking warfarin and commonly prescribed antibiotics and antifungals simultaneously. Gen Dent. 2012;60:454-6. [PubMed] [Google Scholar]
  290. Zanon E, Martinelli F, Bacci C, Cordioli G, Girolami A. Safety of dental extraction among consecutive patients on oral anticoagulant treatment managed using a specific dental management protocol. Blood coagulation & fibrinolysis 2003;14:27-30. [CrossRef] [Google Scholar]
  291. Zhang Q, Bal dit Sollier C, Simoneau G, Alvarez JC, Pruvot S, Aubourg R, Berge N, Bergmann JF, Mouly S, Mahé I. Ineraction between acetominophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial. Eur J Clin Pharmacol 2011;67:309-14. [CrossRef] [PubMed] [Google Scholar]
  292. Zhang Q, Simoneau G, Verstuyft C, Drouet L, Bal dit Sollier C, Alvarez JC, Rizzo-Padoin N, Bergmann JF, Becquemont L, Mouly S. Amoxicillin/clavulanic acid- warfarin drug interaction : a randomized controlled trial. Br J Clin Pharmacol 2011;71:232-36. [CrossRef] [PubMed] [Google Scholar]
  293. Romond KK, Miller CS, Henry RG. Dental management considerations for a patient taking dabigatran etexilate: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116:e191-e195. [CrossRef] [PubMed] [Google Scholar]
  294. Meyer G, Belmont L. Cancer and venous thromboembolism. Rev Mal Resp 2011;25:443-52. [CrossRef] [Google Scholar]
  295. Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Strangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for dabigatran reversal. New Engl J Med 2015, Jun 22. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.